NCT04617275 is a Phase 2 clinical trial of PF-06882961 in Diabetes, sponsored by Pfizer.

Who is sponsoring NCT04617275?

NCT04617275 is sponsored by Pfizer.

What drugs are being tested in NCT04617275?

Interventions in NCT04617275: PF-06882961, Placebo.

What condition does NCT04617275 study?

NCT04617275 studies Diabetes, Obesity.

Is NCT04617275 still recruiting?

NCT04617275 is currently completed. Last updated 8 December 2022.

Are results published for NCT04617275?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-12-08 · How we verify

NCT04617275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

Completed Phase 2 Results posted Last updated 8 December 2022

What this trial tests

Phase 2 trial testing PF-06882961 in Diabetes in 151 participants. Completed in 17 November 2021.

Timeline

6 January 2021

Primary endpoint
17 November 2021

17 November 2021

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	151
Start date	6 January 2021
Primary completion	17 November 2021
Estimated completion	17 November 2021
Sites	38 locations across United States

Drugs / interventions tested

PF-06882961 (pf-06882961) — full drug profile →
Placebo

Conditions studied

Diabetes — all drugs for Diabetes →
Obesity — all drugs for Obesity →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 75, any sex, with Diabetes or Obesity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity Primary · Baseline through follow-up (Day 112)

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. Assessments of AE intensity were defined as mild (ea

All Causality - Mild

Group	Value	95% CI
Placebo (T2DM)	5
PF-06882961 80 mg BID Low, Slow (T2DM)	4
PF-06882961 80 mg BID High, Slow (T2DM)	10
PF-06882961 120 mg BID Low, Fast (T2DM)	9
PF-06882961 120 mg BID High, Fast (T2DM)	8
PF-06882961 200 mg BID (T2DM)	10
Placebo (Non-diabetic Obesity)	1
PF-06882961 200 mg BID (Non-diabetic Obesity)	6

All Causality - Moderate

Group	Value	95% CI
Placebo (T2DM)	3
PF-06882961 80 mg BID Low, Slow (T2DM)	8
PF-06882961 80 mg BID High, Slow (T2DM)	3
PF-06882961 120 mg BID Low, Fast (T2DM)	5
PF-06882961 120 mg BID High, Fast (T2DM)	6
PF-06882961 200 mg BID (T2DM)	3
Placebo (Non-diabetic Obesity)	3
PF-06882961 200 mg BID (Non-diabetic Obesity)	11

All Causality - Severe

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	1
PF-06882961 120 mg BID Low, Fast (T2DM)	2
PF-06882961 120 mg BID High, Fast (T2DM)	1
PF-06882961 200 mg BID (T2DM)	1
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	1

Treatment Related - Mild

Group	Value	95% CI
Placebo (T2DM)	2
PF-06882961 80 mg BID Low, Slow (T2DM)	4
PF-06882961 80 mg BID High, Slow (T2DM)	8
PF-06882961 120 mg BID Low, Fast (T2DM)	3
PF-06882961 120 mg BID High, Fast (T2DM)	7
PF-06882961 200 mg BID (T2DM)	9
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	5

Treatment Related - Moderate

Group	Value	95% CI
Placebo (T2DM)	2
PF-06882961 80 mg BID Low, Slow (T2DM)	4
PF-06882961 80 mg BID High, Slow (T2DM)	2
PF-06882961 120 mg BID Low, Fast (T2DM)	3
PF-06882961 120 mg BID High, Fast (T2DM)	7
PF-06882961 200 mg BID (T2DM)	3
Placebo (Non-diabetic Obesity)	1
PF-06882961 200 mg BID (Non-diabetic Obesity)	11

Treatment Related - Severe

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	2
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	1
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	1

Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) Secondary · Baseline through Visit 10 (Day 91)

Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion.

Group	Value	95% CI
Placebo (T2DM)	12
PF-06882961 80 mg BID Low, Slow (T2DM)	16
PF-06882961 80 mg BID High, Slow (T2DM)	17
PF-06882961 120 mg BID Low, Fast (T2DM)	20
PF-06882961 120 mg BID High, Fast (T2DM)	17
PF-06882961 200 mg BID (T2DM)	14
Placebo (Non-diabetic Obesity)	4
PF-06882961 200 mg BID (Non-diabetic Obesity)	9

Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria Secondary · Baseline through Visit 10 (Day 91)

Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP \>=30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>=20 mmHg.

Supine SBP <90 mmHg

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Supine SBP Increase >=30 mmHg

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	2
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	4
PF-06882961 200 mg BID (T2DM)	1
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Supine SBP Decrease >=30 mmHg

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	2
PF-06882961 80 mg BID High, Slow (T2DM)	1
PF-06882961 120 mg BID Low, Fast (T2DM)	3
PF-06882961 120 mg BID High, Fast (T2DM)	2
PF-06882961 200 mg BID (T2DM)	1
Placebo (Non-diabetic Obesity)	1
PF-06882961 200 mg BID (Non-diabetic Obesity)	2

Supine DBP <50 mmHg

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Supine DBP Increase >=20 mmHg

Group	Value	95% CI
Placebo (T2DM)	1
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	2
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	2
PF-06882961 200 mg BID (T2DM)	1
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Supine DBP Decrease >=20 mmHg

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	1
PF-06882961 80 mg BID High, Slow (T2DM)	1
PF-06882961 120 mg BID Low, Fast (T2DM)	1
PF-06882961 120 mg BID High, Fast (T2DM)	1
PF-06882961 200 mg BID (T2DM)	1
Placebo (Non-diabetic Obesity)	1
PF-06882961 200 mg BID (Non-diabetic Obesity)	1

Supine Pulse Rate <40 bpm

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Supine Pulse Rate >120 bpm

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria Secondary · Baseline through Visit 10 (Day 91)

ECG assessments included pulse rate (PR), QT, heart rate, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300 msec, or baseline (BL) \>200 msec and \>=25% increase from BL, or BL \<=200 msec and \>=50% increase from BL; QRS interval value \>= 140msec, or \>=50% increase from BL; QTcF value \>450 and \<=480 msec, or \>480 and \<=500 msec, or \>500 msec, or increase from BL\>30 and \<=60 msec, or \>60msec.

PR interval >=300 msec

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

%Change in PR interval >=25/50%

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

QRS interval >=140 msec

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

%Change in QRS interval >=50%

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

QTcF interval >450 and <=480 msec

Group	Value	95% CI
Placebo (T2DM)	1
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	2
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	1
PF-06882961 200 mg BID (Non-diabetic Obesity)	1

QTcF interval >480 and <=500 msec

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	1
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

QTcF interval >500 msec

Group	Value	95% CI
Placebo (T2DM)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Change in QTcF interval >30 and <=60 msec

Group	Value	95% CI
Placebo (T2DM)	2
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	1
PF-06882961 120 mg BID High, Fast (T2DM)	3
PF-06882961 200 mg BID (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Secondary · Week 0, 2, 4, 6, 8, 10, 12, 13-14

The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Participants who responded "yes" to the questions will be counted. Data relevant to the assessment of suicidality were mapped to the Columbia-Classification Algorithm of Suicide Assessment (C-CASA) codes.

Week 0 - <1> Completed Suicide

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 0 - <2> Suicide Attempt

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 0 - <4> Suicidal Ideation

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 0 - <7> Self-injurious Behavior, No Suicidal Intent

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 2 - <1> Completed Suicide

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 2 - <2> Suicide Attempt

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9) Secondary · Week 0, 2, 4, 6, 8, 10, 12, 13-14.

The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 were completed by participants and reviewed by site staff at the pre-defined time points.

Week 0 - Little Interest/Pleasure in Things - Not At All

Group	Value	95% CI
Placebo (T2DM)	15
Placebo (Non-diabetic Obesity)	6
PF-06882961 80 mg BID Low, Slow (T2DM)	16
PF-06882961 80 mg BID High, Slow (T2DM)	20
PF-06882961 120 mg BID Low, Fast (T2DM)	20
PF-06882961 120 mg BID High, Fast (T2DM)	20
PF-06882961 200 mg BID (T2DM)	19
PF-06882961 200 mg BID (Non-diabetic Obesity)	21

Week 0 - Little Interest/Pleasure in Things - Several Days

Group	Value	95% CI
Placebo (T2DM)	1
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	3
PF-06882961 80 mg BID High, Slow (T2DM)	1
PF-06882961 120 mg BID Low, Fast (T2DM)	1
PF-06882961 120 mg BID High, Fast (T2DM)	1
PF-06882961 200 mg BID (T2DM)	1
PF-06882961 200 mg BID (Non-diabetic Obesity)	1

Week 0 - Little Interest/Pleasure in Things - More Than Half the Days

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	1
PF-06882961 80 mg BID High, Slow (T2DM)	1
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	1
PF-06882961 200 mg BID (T2DM)	1
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 0 - Little Interest/Pleasure in Things - Nearly Every Day

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 0 - Feeling Down Depressed or Hopeless - Not At All

Group	Value	95% CI
Placebo (T2DM)	14
Placebo (Non-diabetic Obesity)	6
PF-06882961 80 mg BID Low, Slow (T2DM)	19
PF-06882961 80 mg BID High, Slow (T2DM)	18
PF-06882961 120 mg BID Low, Fast (T2DM)	19
PF-06882961 120 mg BID High, Fast (T2DM)	22
PF-06882961 200 mg BID (T2DM)	19
PF-06882961 200 mg BID (Non-diabetic Obesity)	19

Week 0 - Feeling Down Depressed or Hopeless - Several Days

Group	Value	95% CI
Placebo (T2DM)	2
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	1
PF-06882961 80 mg BID High, Slow (T2DM)	3
PF-06882961 120 mg BID Low, Fast (T2DM)	1
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	2
PF-06882961 200 mg BID (Non-diabetic Obesity)	3

Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	1
PF-06882961 120 mg BID Low, Fast (T2DM)	1
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day

Group	Value	95% CI
Placebo (T2DM)	0
Placebo (Non-diabetic Obesity)	0
PF-06882961 80 mg BID Low, Slow (T2DM)	0
PF-06882961 80 mg BID High, Slow (T2DM)	0
PF-06882961 120 mg BID Low, Fast (T2DM)	0
PF-06882961 120 mg BID High, Fast (T2DM)	0
PF-06882961 200 mg BID (T2DM)	0
PF-06882961 200 mg BID (Non-diabetic Obesity)	0

Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 Secondary · Baseline, Week 2

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Group	Value	95% CI
Placebo (T2DM)	-5.63	-19.00 – 7.74
PF-06882961 80 mg BID Low, Slow (T2DM)	-3.32	-14.62 – 7.97
PF-06882961 80 mg BID High, Slow (T2DM)	-23.04	-34.05 – -12.03
PF-06882961 120 mg BID Low, Fast (T2DM)	-36.48	-47.44 – -25.52
PF-06882961 120 mg BID High, Fast (T2DM)	-39.29	-50.23 – -28.35
PF-06882961 200 mg BID (T2DM)	-25.15	-36.59 – -13.72

CFB in Fasting Plasma Glucose at Week 4 Secondary · Baseline, Week 4

Group	Value	95% CI
Placebo (T2DM)	-13.12	-26.88 – 0.64
PF-06882961 80 mg BID Low, Slow (T2DM)	-16.45	-28.11 – -4.79
PF-06882961 80 mg BID High, Slow (T2DM)	-32.77	-43.98 – -21.55
PF-06882961 120 mg BID Low, Fast (T2DM)	-45.92	-57.20 – -34.64
PF-06882961 120 mg BID High, Fast (T2DM)	-48.97	-60.52 – -37.42
PF-06882961 200 mg BID (T2DM)	-41.60	-53.38 – -29.83

CFB in Fasting Plasma Glucose at Week 6 Secondary · Baseline, Week 6

Group	Value	95% CI
Placebo (T2DM)	-3.75	-19.85 – 12.35
PF-06882961 80 mg BID Low, Slow (T2DM)	-29.33	-43.35 – -15.31
PF-06882961 80 mg BID High, Slow (T2DM)	-36.70	-50.13 – -23.27
PF-06882961 120 mg BID Low, Fast (T2DM)	-43.82	-57.90 – -29.75
PF-06882961 120 mg BID High, Fast (T2DM)	-49.22	-63.14 – -35.31
PF-06882961 200 mg BID (T2DM)	-37.38	-51.77 – -22.99

CFB in Fasting Plasma Glucose at Week 8 Secondary · Baseline, Week 8

Group	Value	95% CI
Placebo (T2DM)	-5.90	-20.83 – 9.04
PF-06882961 80 mg BID Low, Slow (T2DM)	-33.69	-47.42 – -19.96
PF-06882961 80 mg BID High, Slow (T2DM)	-31.57	-44.56 – -18.58
PF-06882961 120 mg BID Low, Fast (T2DM)	-52.84	-66.55 – -39.13
PF-06882961 120 mg BID High, Fast (T2DM)	-39.69	-53.63 – -25.75
PF-06882961 200 mg BID (T2DM)	-48.02	-62.47 – -33.57

CFB in Fasting Plasma Glucose at Week 10 Secondary · Baseline, Week 10

Group	Value	95% CI
Placebo (T2DM)	-23.39	-39.07 – -7.71
PF-06882961 80 mg BID Low, Slow (T2DM)	-36.24	-51.69 – -20.78
PF-06882961 80 mg BID High, Slow (T2DM)	-38.21	-52.17 – -24.26
PF-06882961 120 mg BID Low, Fast (T2DM)	-57.36	-72.43 – -42.29
PF-06882961 120 mg BID High, Fast (T2DM)	-22.08	-36.88 – -7.29
PF-06882961 200 mg BID (T2DM)	-37.81	-53.52 – -22.11

CFB in Fasting Plasma Glucose at Week 12 Secondary · Baseline, Week 12

Group	Value	95% CI
Placebo (T2DM)	-13.09	-29.75 – 3.57
PF-06882961 80 mg BID Low, Slow (T2DM)	-41.74	-58.49 – -25.00
PF-06882961 80 mg BID High, Slow (T2DM)	-40.41	-55.25 – -25.57
PF-06882961 120 mg BID Low, Fast (T2DM)	-53.94	-70.26 – -37.63
PF-06882961 120 mg BID High, Fast (T2DM)	-23.34	-39.52 – -7.17
PF-06882961 200 mg BID (T2DM)	-37.48	-55.27 – -19.69

Adverse events — posted to ClinicalTrials.gov

Time frame: Baseline through follow-up (Day 112-119).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo (T2DM)

Serious: 0/16 (0%)

Deaths: 0/16

Placebo (Non-diabetic Obesity)

Serious: 0/6 (0%)

Deaths: 0/6

PF-06882961 80 mg BID Low, Slow (T2DM)

Serious: 0/20 (0%)

Deaths: 0/20

PF-06882961 80 mg BID High, Slow (T2DM)

Serious: 0/22 (0%)

Deaths: 0/22

PF-06882961 120 mg BID Low, Fast (T2DM)

Serious: 0/22 (0%)

Deaths: 0/22

PF-06882961 120 mg BID High, Fast (T2DM)

Serious: 0/22 (0%)

Deaths: 0/22

PF-06882961 200 mg BID (T2DM)

Serious: 0/21 (0%)

Deaths: 0/21

PF-06882961 200 mg BID (Non-diabetic Obesity)

Serious: 0/22 (0%)

Deaths: 0/22

Other adverse events (45 terms — click to expand)

Reaction	System	Placebo (T2DM)	Placebo (Non-diabetic Obes…	PF-06882961 80 mg BID Low,…	PF-06882961 80 mg BID High…	PF-06882961 120 mg BID Low…	PF-06882961 120 mg BID Hig…	PF-06882961 200 mg BID (T2…	PF-06882961 200 mg BID (No…
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Hypoglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—
Palpitations	Cardiac disorders	—	—	—	—	—	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Eructation	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—
Muscle strain	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Blood triglycerides increased	Investigations	—	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Pinguecula	Eye disorders	—	—	—	—	—	—	—	—
Faeces discoloured	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Food poisoning	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—
Chest discomfort	General disorders	—	—	—	—	—	—	—	—
Chest pain	General disorders	—	—	—	—	—	—	—	—
Pre-existing condition improved	General disorders	—	—	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—	—	—
Gastroenteritis viral	Infections and infestations	—	—	—	—	—	—	—	—
Infected bite	Infections and infestations	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—
Electrocardiogram QT prolonged	Investigations	—	—	—	—	—	—	—	—
Dyslipidaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Musculoskeletal stiffness	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Amnesia	Nervous system disorders	—	—	—	—	—	—	—	—
Neuropathy peripheral	Nervous system disorders	—	—	—	—	—	—	—	—
Paraesthesia	Nervous system disorders	—	—	—	—	—	—	—	—

Data from ClinicalTrials.gov NCT04617275 adverse events section.

Sponsor's own description

This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in non-diabetic adults with obesity

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, et al · · 2022 · cited 245× · PMID 36031641 · DOI 10.1038/s41392-022-01149-x
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Saxena AR, Frias JP, Gorman DN, Lopez RN, et al · · 2023 · cited 31× · PMID 37311722 · DOI 10.1111/dom.15168
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
Nicze M, Dec A, Borówka M, Krzyżak D, et al · · 2024 · cited 9× · PMID 39125772 · DOI 10.3390/ijms25158202
Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.
Buckeridge C, Cobain S, Bays HE, Matsuoka O, et al · · 2025 · cited 8× · PMID 40539310 · DOI 10.1111/dom.16534
58<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : Stockholm, Sweden, 19 - 23 September 2022.
· 2022 · cited 6× · PMID 35920845 · DOI 10.1007/s00125-022-05755-w
Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach.
Șeremet OC, Pușcașu C, Andrei C, Nițulescu G, et al · · 2025 · cited 1× · PMID 41303737 · DOI 10.3390/medicina61111902

Verify or expand the search:

Other trials of PF-06882961

Trials testing the same drug.

NCT06910839 — Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either · Phase 1 · terminated
NCT05093205 — STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETIC · Phase 1 · completed
NCT04889157 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults Wit · Phase 1 · completed
NCT04621227 — Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In · Phase 1 · completed
NCT04552470 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults Wi · Phase 1 · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04617275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 8 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04617275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04617275

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of PF-06882961

Other recruiting trials for Diabetes

Other Pfizer trials

Verify against primary sources